Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1261

—

24f66cd4-e059-5cce-86bc-9c47df864ca7

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • TNFA_SIGNALING_VIA_NFKB+0.656
  • MYC_TARGETS_V2+0.519
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.437
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.433
  • CHOLESTEROL_HOMEOSTASIS+0.418
  • IL6_JAK_STAT3_SIGNALING+0.397
  • UV_RESPONSE_UP+0.376
  • INFLAMMATORY_RESPONSE+0.375
  • ANGIOGENESIS+0.345
  • HYPOXIA+0.335

Top 10 suppressed

  • PROTEIN_SECRETION-0.408
  • MITOTIC_SPINDLE-0.250
  • NOTCH_SIGNALING-0.202
  • BILE_ACID_METABOLISM-0.195
  • UV_RESPONSE_DN-0.151
  • E2F_TARGETS-0.127
  • PEROXISOME-0.126
  • G2M_CHECKPOINT-0.101
  • SPERMATOGENESIS-0.084
  • HEME_METABOLISM-0.082

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1MDT-AP-0532
medullo-epn-umap@date-based
MedMedulloblastoma0.863
2BS_WWKNJSJ5
brain-umap@2
ATRT—0.853
3X3a5c813b.6c47.49aa.916c.bcddbafdd54b
lung-landscapes@6
—cohortA10.847
4MDT-AP-2001
medullo-epn-umap@date-based
MedMedulloblastoma0.844
5AUR-AER2-TTP1-A-1-1-R-A742-41
breast-umap@18
—C0.844
6MNG302
mng-umap@100
——0.843
7MNG1163
mng-umap@100
——0.842
8SRR1466975
brain-umap@2
GTEX—0.838
9SJEPD001508_D1.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.831
10BS_8RHPJ740
medullo-epn-umap@date-based
EPNEPN Tumor0.826

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 33 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
TNFA_SIGNALING_VIA_NFKB0.656Inavolisib— uncovered
MYC_TARGETS_V20.519Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.437Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.433Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.418Remibrutinib— uncovered
IL6_JAK_STAT3_SIGNALING0.397Inavolisib— uncovered
UV_RESPONSE_UP0.376Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.375Idelalisib— uncovered
ANGIOGENESIS0.345Remibrutinib— uncovered
HYPOXIA0.335Idelalisib— uncovered
COAGULATION0.333Binimetinib— uncovered
MYC_TARGETS_V10.327Inavolisib— uncovered
MYOGENESIS0.321Inavolisib— uncovered
APOPTOSIS0.315Idelalisib— uncovered
P53_PATHWAY0.312Idelalisib— uncovered
IL2_STAT5_SIGNALING0.268Idelalisib— uncovered
ESTROGEN_RESPONSE_LATE0.253Idelalisib— uncovered
TGF_BETA_SIGNALING0.240Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.226Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.225Inavolisib— uncovered